Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Advancing the care of beta-thalassaemia patients with novel therapies.Blood Transfus. 2022; 20: 78-88
- 2021 update on clinical trials in beta-thalassemia.Am J Hematol. 2021; 96: 1518-1531
- Emerging therapies in beta-thalassemia: toward a new era in management.Expert Opin Emerg Drugs. 2020; 25: 113-122
- beta thalassemia: new therapeutic options beyond transfusion and iron chelation.Drugs. 2020; 80: 1053-1063
- Pharmacological Induction of Fetal Hemoglobin in beta-Thalassemia and Sickle Cell Disease: An Updated Perspective.Pharmaceuticals (Basel). 2022; 15: 753
- A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease.Haematologica. 2020; 105: 623-631
- Imara announces results of interim analyses of Tovinontrine (IMR-687) Phase 2B clinical trials in Sickle Cell Disease and Beta-Thalassemia. Press Release.(Available at:) (Accessed October 1, 2022)
- Sotatercept, a novel transforming growth factor beta ligand trap, improves anemia in beta-thalassemia: a phase II, open-label, dose-finding study.Haematologica. 2019; 104: 477-484
- The use of luspatercept for thalassemia in adults.Blood Adv. 2021; 5: 326-333
- Luspatercept for beta-thalassemia: beyond red blood cell transfusions.Expert Opin Biol Ther. 2021; 21: 1363-1371
- Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis.Nat Med. 2014; 20: 408-414
- Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia.Blood. 2014; 123: 3864-3872
- Smad2/3-pathway ligand trap luspatercept enhances erythroid differentiation in murine beta-thalassaemia by increasing GATA-1 availability.J Cell Mol Med. 2020; 24: 6162-6177
- Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia.Blood. 2019; 133: 1279-1289
- A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent beta-Thalassemia.N Engl J Med. 2020; 382: 1219-1231
- Health-Related Quality of Life Outcomes for Patients with Transfusion-Dependent Beta-Thalassemia Treated with Luspatercept in the Believe Trial [abstract].Blood. 2020; 136: 8-9
- Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in β-Thalassemia with Luspatercept: Longitudinal Results of the Believe Trial [abstract].Blood. 2020; 136: 45-46
- Longitudinal effect of luspatercept treatment on iron overload and iron chelation therapy (ICT) in adult patients (pts) with β-thalassemia in the BELIEVE trial [abstract].Blood. 2020; 136: 47-48
- label. Silver Spring, MD: FDA.(Available at:) (Accessed October 1, 2022)
- Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020. Amsterdam: EMA.(Available at:) (Accessed October 1, 2022)
- S270: Longer-term analysis of efficacy of luspatercept versus placebo in patients with transfusion-dependent beta-thalassemia enrolled in the BELIEVE study.HemaSphere. 2022; 6: 171-172
- P1518: Long-term safety results of the BELIEVE study of Luspatercept in adults with Beta-Thalassemia.HemaSphere. 2022; 6: 1399-1400
- Luspatercept for the treatment of anaemia in non-transfusion-dependent beta-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.Lancet Haematol. 2022; 9: e733-e744
- Phase 1 Single- and Multiple-Ascending-Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers.Clin Pharmacol Drug Dev. 2019; 8: 246-259
- Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency.N Engl J Med. 2019; 381: 933-944
- Mitapivat versus Placebo for Pyruvate Kinase Deficiency.N Engl J Med. 2022; 386: 1432-1442
- ACTIVATE-T: a phase 3, open-label, multicenter study of mitapivat in adults with pyruvate kinase deficiency who are regularly transfused.Eur Hematol Assoc. 2021; 9: 17
- Phase 1 multiple ascending dose study of safety, tolerability, and pharmacokinetics/pharmacodynamics of Mitapivat (AG-348) in subjects with sickle cell disease.Blood. 2020; 136: 21-22
- Decreased activity and stability of pyruvate kinase in hereditary hemolytic anemia: a potential target for therapy by AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase.Blood. 2019; 134: 3506
- The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a beta-thalassemia mouse model.J Clin Invest. 2021; 131: e144206
- Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent alpha-thalassaemia or beta-thalassaemia: an open-label, multicentre, phase 2 study.Lancet. 2022; 400: 493-501
- S103: trial in progress: a phase 2, open-label study evaluating the safety and efficacy of the pkr activator etavopivat (ft-4202) in patients with thalassemia or sickle cell disease.HemaSphere. 2022; 6: 2
- Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease.Blood. 2021; 138: 4162
- Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia.Blood. 2008; 112: 875-885
- Short-term administration of JAK2 inhibitors reduces splenomegaly in mouse models of beta-thalassemia intermedia and major.Haematologica. 2018; 103: e46-e49
- Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study.Blood. 2018; 131: 263-265
- Efficacy and safety of ruxolitinib in ineffective erythropoiesis suppression as a pretransplantation treatment for pediatric patients with beta-thalassemia major.Pediatr Blood Cancer. 2021; 68: e29338
- Bitopertin, a selective oral GLYT1 inhibitor, improves anemia in a mouse model of β-thalassemia.JCI Insight. 2019; 4: e130111
- Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non-transfusion-dependent beta-thalassaemia.Br J Haematol. 2021; 194: 474-477
- Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload.J Clin Invest. 2011; 121: 4880-4888
- Minihepcidin peptides as disease modifiers in mice affected by beta-thalassemia and polycythemia vera.Blood. 2016; 128: 265-276
- Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult beta-thalassemia major.Haematologica. 2020; 105: 1835-1844
- Deletion of TMPRSS6 attenuates the phenotype in a mouse model of beta-thalassemia.Blood. 2012; 119: 5021-5029
- Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice.Blood. 2016; 127: 2327-2336
- Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice.J Clin Invest. 2013; 123: 1531-1541
- An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine beta-thalassemia intermedia.Blood. 2013; 121: 1200-1208
- Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in beta-thalassemia: current evidence and future clinical development.Expert Rev Hematol. 2021; 14: 633-644
- Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of beta-thalassemia.J Clin Invest. 2019; 130: 491-506
- The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of beta-Thalassemia.Int J Mol Sci. 2021; 22
- Oral ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers.Am J Hematol. 2020; 95: 68-77
- S272: safety and preliminary pharmacodynamic effects of the ferroportin inhibitor vamifeport (VIT-2763) in patients with non-transfusion-dependent beta thalassemia (NTDT): results from a phase 2A study.HemaSphere. 2022; 6: 173-174
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
